Главная страница › UK approves use of Covid antibody treatment that appears to reduce risk of hospitalization and death in some high-risk adults by almost 80% › UK approves use of Covid antibody treatment that appears to reduce risk of hospitalization and death in some high-risk adults by almost 80%

UK approves use of Covid antibody treatment that appears to reduce risk of hospitalization and death in some high-risk adults by almost 80%

Primary tabs

UK approves use of Covid antibody treatment that appears to reduce risk of hospitalization and death in some high-risk adults by almost 80%

Thu, 2021-12-02 11:20 — mike kraft

UK approves use of Covid antibody treatment that appears to reduce risk of hospitalization and death in some high-risk adults by almost 80% An antibody treatment which has been found to reduce the risk of hospitalization and death from Covid-19 by up to 79% in high-risk adults has been approved for use in the United Kingdom. By Rhea Mogul, Adam Renton, Sheena McKenzie & Ed Upright, CNN CNN

...

Xevudy, also known as sotrovimab, was approved for use in patients aged 12 and above by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday, the MHRA said in a statement.

The drug “was found to be safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 infection who are at an increased risk of developing severe disease,” the statement added.

Sotrovimab was developed by London-based GlaxoSmithKline (GSK) and Vir Biotechnology, based in California. It “retains activity against all tested variants of concern, including key mutations of Omicron,” according to a statement released Thursday by maker GSK.

It is the second monoclonal antibody therapeutic to be approved by the UK drugs watchdog, after Ronapreve, made by Regeneron. ...

Country / Region Tags:

General Topic Tags: